Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease

Li, Ran; She, Dunmin; Ye, Zhengqin; Fang, Ping; Zong, Guannan; Zhao, Yi; Hu, Keke; Zhang, Liya; Sha, Lei; Zhang, Ke‐Qin; Xue, Ying

doi:10.2147/dmso.s353717

Cited by 2 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endogenous and pharmacological activation of the GLP-1 receptor (GLP-1R) axis is thought to be reno-protective in DM ( 177 ). GLP-1R agonists (GLP-1RAs) are recognized as a new class of hypoglycemic agents with potential for the prevention and treatment of DKD ( 189 ).…”

Section: Treatmentmentioning

confidence: 99%

“…GLP-1 has a natriuretic effect in the proximal renal tubules, the beneficial effects of GLP-1 and GLP-1RA may be related to the regulation of the RAAS ( 177 ). GLP-1RA might exert reno-protective effects by stimulating proximal tubular natriuretic peptide in the proximal tubules, modulating cAMP/PKA signaling and inhibiting RAAS ( 178 ).…”

Section: Treatmentmentioning

confidence: 99%

“…It plays a reno-protective role by reducing Ang II levels ( 193 ). Treatment with GLP-1RA significantly attenuated high glucose-induced tubule damage in DKD kidney tissues and TECs cells ( 177 ).…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

et al. 2023

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a chronic complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. Currently, there are limited therapeutic drugs available for DKD. While previous research has primarily focused on glomerular injury, recent studies have increasingly emphasized the role of renal tubular injury in the pathogenesis of DKD. Various factors, including hyperglycemia, lipid accumulation, oxidative stress, hypoxia, RAAS, ER stress, inflammation, EMT and programmed cell death, have been shown to induce renal tubular injury and contribute to the progression of DKD. Additionally, traditional hypoglycemic drugs, anti-inflammation therapies, anti-senescence therapies, mineralocorticoid receptor antagonists, and stem cell therapies have demonstrated their potential to alleviate renal tubular injury in DKD. This review will provide insights into the latest research on the mechanisms and treatments of renal tubular injury in DKD.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%